Symbols / EVAX
EVAX Chart
About
Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based cancer vaccine that has completed Phase 1/2a trial to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers, including non-small cell lung cancer. Its programs also include vaccines that are in pre-clinical stage, which includes EVX-B1 for the prevention of S. aureus-induced skin and soft tissue infections in patients undergoing elective abdominal hernia surgery; EVX-B2 to target diseases caused by N. gonorrhoeae; EVX-B3 for eliciting strong humoral antibody and cellular immune response to the bacterial pathogen; and EVX-V1, a viral vaccine product candidate for targeting Cytomegalovirus. The company was formerly known as Evaxion Biotech A/S and changed its name to Evaxion A/S in May 2025. Evaxion A/S was incorporated in 2008 and is based in Horsholm, Denmark.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 28.94M |
| Enterprise Value | 1.09B | Income | -5.42M | Sales | 7.65M |
| Book/sh | 2.61 | Cash/sh | 0.03 | Dividend Yield | — |
| Payout | 0.00% | Employees | 46 | IPO | — |
| P/E | — | Forward P/E | -231.33 | PEG | — |
| P/S | 3.78 | P/B | 1.33 | P/C | — |
| EV/EBITDA | -123.53 | EV/Sales | 142.88 | Quick Ratio | — |
| Current Ratio | — | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -4.00 | EPS next Y | -0.01 | EPS Growth | — |
| Revenue Growth | 148.30% | Earnings | 2025-11-06 07:00 | ROA | -25.62% |
| ROE | -64.99% | ROIC | — | Gross Margin | 100.00% |
| Oper. Margin | 40.35% | Profit Margin | -70.82% | Shs Outstand | 8.34M |
| Shs Float | 212.41M | Short Float | 1.00% | Short Ratio | 0.90 |
| Short Interest | — | 52W High | 12.15 | 52W Low | 1.20 |
| Beta | 0.29 | Avg Volume | 78.71K | Volume | 17.67K |
| Target Price | $11.75 | Recom | Strong_buy | Prev Close | $3.24 |
| Price | $3.47 | Change | 7.10% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$11.75
Mean price target
2. Current target
$3.47
Latest analyst target
3. DCF / Fair value
$11.75
Proxy: analyst mean price target (no FCF/EPS data available).
Ratings
Current target
$3.47
Low
$10.00
High
$16.00
Mean
$11.75
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-10-30 | init | Edward Jones | — → Buy | $10 |
| 2025-10-20 | main | Lake Street | Buy → Buy | $11 |
| 2025-10-20 | reit | HC Wainwright & Co. | Buy → Buy | $16 |
| 2025-09-25 | main | HC Wainwright & Co. | Buy → Buy | $16 |
| 2025-04-02 | reit | HC Wainwright & Co. | Buy → Buy | $14 |
| 2025-02-20 | reit | HC Wainwright & Co. | Buy → Buy | $14 |
| 2025-02-04 | main | Lake Street | Buy → Buy | $6 |
| 2025-02-03 | reit | HC Wainwright & Co. | Buy → Buy | $14 |
| 2024-11-01 | reit | HC Wainwright & Co. | Buy → Buy | $14 |
| 2024-09-26 | reit | HC Wainwright & Co. | Buy → Buy | $14 |
| 2024-09-20 | reit | HC Wainwright & Co. | Buy → Buy | $14 |
| 2024-08-16 | reit | HC Wainwright & Co. | Buy → Buy | $14 |
| 2024-08-01 | reit | HC Wainwright & Co. | Buy → Buy | $14 |
| 2024-06-04 | reit | HC Wainwright & Co. | Buy → Buy | $14 |
| 2024-04-03 | reit | HC Wainwright & Co. | Buy → Buy | $14 |
| 2024-04-02 | up | Ladenburg Thalmann | Neutral → Buy | $8 |
| 2024-03-20 | reit | HC Wainwright & Co. | Buy → Buy | $14 |
| 2024-02-12 | init | HC Wainwright & Co. | — → Buy | $14 |
- Evaxion Biotech stock holds Buy rating at H.C. Wainwright after ASH data - Investing.com Wed, 10 Dec 2025 08
- Evaxion (NASDAQ: EVAX) sets 2026 calendar: March, May, Aug., Nov. updates, AGM - Stock Titan Wed, 12 Nov 2025 08
- Lake Street Raises Evaxion (EVAX) PT to $11 Following Positive Two-Year EVX-01 Melanoma Data - Yahoo Finance Sun, 26 Oct 2025 07
- Lake Street Maintains Evaxion A (EVAX) Buy Recommendation - Nasdaq Mon, 20 Oct 2025 07
- New Analyst Forecast: $EVAX Given 'Buy' Rating - Quiver Quantitative hu, 30 Oct 2025 07
- Merck in-licenses Evaxion vaccine candidate in a deal worth up to $600M - Seeking Alpha hu, 25 Sep 2025 07
- These 3 Penny Stocks are Soaring Today: PLUS, EVAX, DVLT - 24/7 Wall St. hu, 25 Sep 2025 07
- Evaxion (NASDAQ:EVAX) Stock Rockets After AI-Powered Cancer Vaccine Breakthrough - TechStock² Wed, 15 Oct 2025 07
- Evaxion Stock Jumps A Whopping 43% Pre-Market – Here’s What Happened - Stocktwits Wed, 24 Sep 2025 07
- AI vaccine developer Evaxion to share 2026 milestones in San Francisco - Stock Titan Wed, 07 Jan 2026 08
- Maxim Group initiates Evaxion Biotech stock with buy on AI platform By Investing.com - Investing.com South Africa hu, 19 Feb 2026 08
- Evaxion: Progress Unrecognized By Market And A Catalyst-Full 2025 (NASDAQ:EVAX) - Seeking Alpha Mon, 26 May 2025 07
- Evaxion Appoints Helen Tayton-Martin As Chief Executive - Stocktwits Mon, 27 Oct 2025 07
- $592M Potential Deal: Evaxion's AI-Powered Vaccine Platform Lands Major MSD Partnership for Novel Pathogen - Stock Titan hu, 25 Sep 2025 07
- H.C. Wainwright reiterates Buy rating on Evaxion Biotech stock with $16 target - Investing.com Mon, 20 Oct 2025 07
Insider Transactions
No recent insider transactions.
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 285.95K | 1.00K | 84.32K | 12.83K |
| TaxRateForCalcs | 0.07 | 0.04 | 0.04 | 0.01 |
| NormalizedEBITDA | -13.87M | -21.43M | -24.68M | -25.49M |
| TotalUnusualItems | 4.08M | 25.00K | 2.11M | 1.28M |
| TotalUnusualItemsExcludingGoodwill | 4.08M | 25.00K | 2.11M | 1.28M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -10.57M | -22.12M | -23.17M | -24.53M |
| ReconciledDepreciation | 607.00K | 615.00K | 571.00K | 344.00K |
| EBITDA | -9.79M | -21.40M | -22.57M | -24.21M |
| EBIT | -10.39M | -22.02M | -23.14M | -24.55M |
| NetInterestIncome | -708.00K | -743.00K | -785.00K | -159.00K |
| InterestExpense | 962.00K | 897.00K | 798.00K | 159.00K |
| InterestIncome | 254.00K | 154.00K | 13.00K | 0.00 |
| NormalizedIncome | -14.37M | -22.15M | -25.19M | -25.80M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -10.57M | -22.12M | -23.17M | -24.53M |
| TotalExpenses | 18.08M | 22.27M | 25.26M | 25.83M |
| TotalOperatingIncomeAsReported | -14.73M | -22.20M | -25.26M | -25.83M |
| DilutedAverageShares | 1.07M | 546.72K | 472.77K | 389.86K |
| BasicAverageShares | 1.07M | 546.72K | 472.77K | 389.86K |
| DilutedEPS | -10.00 | -40.50 | -49.00 | -63.00 |
| BasicEPS | -10.00 | -40.50 | -49.00 | -63.00 |
| DilutedNIAvailtoComStockholders | -10.57M | -22.12M | -23.17M | -24.53M |
| NetIncomeCommonStockholders | -10.57M | -22.12M | -23.17M | -24.53M |
| NetIncome | -10.57M | -22.12M | -23.17M | -24.53M |
| NetIncomeIncludingNoncontrollingInterests | -10.57M | -22.12M | -23.17M | -24.53M |
| NetIncomeContinuousOperations | -10.57M | -22.12M | -23.17M | -24.53M |
| TaxProvision | -788.00K | -790.00K | -772.00K | -178.00K |
| PretaxIncome | -11.36M | -22.91M | -23.94M | -24.71M |
| OtherIncomeExpense | 4.08M | 25.00K | 2.11M | 1.28M |
| GainOnSaleOfSecurity | 4.08M | 25.00K | 2.11M | 1.28M |
| NetNonOperatingInterestIncomeExpense | -708.00K | -743.00K | -785.00K | -159.00K |
| InterestExpenseNonOperating | 962.00K | 897.00K | 798.00K | 159.00K |
| InterestIncomeNonOperating | 254.00K | 154.00K | 13.00K | 0.00 |
| OperatingIncome | -14.73M | -22.20M | -25.26M | -25.83M |
| OperatingExpense | 18.08M | 22.27M | 25.26M | 25.83M |
| DepreciationAmortizationDepletionIncomeStatement | 302.00K | 275.00K | 144.00K | 71.00K |
| DepreciationAndAmortizationInIncomeStatement | 302.00K | 275.00K | 144.00K | 71.00K |
| DepreciationIncomeStatement | 302.00K | 275.00K | 144.00K | 71.00K |
| ResearchAndDevelopment | 10.46M | 11.92M | 17.06M | 19.58M |
| SellingGeneralAndAdministration | 7.32M | 10.08M | 8.06M | 6.18M |
| GeneralAndAdministrativeExpense | 7.32M | 10.08M | 8.06M | 6.18M |
| OtherGandA | 4.73M | 6.95M | 5.90M | 4.03M |
| SalariesAndWages | 2.59M | 3.13M | 2.17M | 2.15M |
| TotalRevenue | 3.34M | 73.00K | 0.00 | 0.00 |
| OperatingRevenue | 3.34M | 73.00K | 0.00 | 0.00 |
| Line Item | 2023-12-31 | |||
|---|---|---|---|---|
| TreasurySharesNumber | 0.00 | |||
| OrdinarySharesNumber | 70.13M | 37.90M | 24.14M | 23.20M |
| ShareIssued | 70.13M | 37.90M | 24.14M | 23.20M |
| NetDebt | 3.12M | 4.46M | ||
| TotalDebt | 10.10M | 10.87M | 10.26M | 3.69M |
| TangibleBookValue | -1.65M | -4.73M | 8.30M | 32.34M |
| InvestedCapital | 6.51M | 3.92M | 16.30M | 33.61M |
| WorkingCapital | 4.40M | 1.27M | 13.22M | 30.38M |
| NetTangibleAssets | -1.65M | -4.73M | 8.30M | 32.34M |
| CapitalLeaseObligations | 1.93M | 2.22M | 2.25M | 2.52M |
| CommonStockEquity | -1.65M | -4.73M | 8.30M | 32.44M |
| TotalCapitalization | 6.36M | 3.76M | 16.17M | 33.48M |
| TotalEquityGrossMinorityInterest | -1.65M | -4.73M | 8.30M | 32.44M |
| StockholdersEquity | -1.65M | -4.73M | 8.30M | 32.44M |
| OtherEquityInterest | 14.02M | 13.66M | 13.19M | |
| GainsLossesNotAffectingRetainedEarnings | -3.60M | -3.77M | -3.65M | -1.32M |
| OtherEquityAdjustments | 79.11M | |||
| ForeignCurrencyTranslationAdjustments | -3.60M | -3.77M | -3.65M | -1.32M |
| RetainedEarnings | -118.54M | -107.97M | -85.84M | -50.43M |
| AdditionalPaidInCapital | 95.94M | 87.45M | 80.73M | 80.43M |
| CapitalStock | 10.52M | 5.90M | 3.89M | 3.75M |
| CommonStock | 10.52M | 5.90M | 3.89M | 3.75M |
| TotalLiabilitiesNetMinorityInterest | 14.14M | 17.62M | 13.72M | 7.73M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 9.77M | 10.53M | 9.96M | 3.40M |
| OtherNonCurrentLiabilities | 10.00K | |||
| LongTermDebtAndCapitalLeaseObligation | 9.63M | 10.38M | 9.82M | 3.25M |
| LongTermCapitalLeaseObligation | 1.62M | 1.90M | 1.95M | 2.21M |
| LongTermDebt | 8.01M | 8.49M | 7.86M | 1.04M |
| LongTermProvisions | 141.00K | 149.00K | 144.00K | 153.00K |
| CurrentLiabilities | 4.37M | 7.08M | 3.76M | 4.32M |
| OtherCurrentLiabilities | 67.00K | 3.02M | 885.00K | 46.00K |
| CurrentDebtAndCapitalLeaseObligation | 473.00K | 485.00K | 439.00K | 440.00K |
| CurrentCapitalLeaseObligation | 314.00K | 326.00K | 303.00K | 314.00K |
| CurrentDebt | 159.00K | 159.00K | 136.00K | 126.00K |
| OtherCurrentBorrowings | 159.00K | 159.00K | 136.00K | 126.00K |
| PensionandOtherPostRetirementBenefitPlansCurrent | 860.00K | 894.00K | 353.00K | 989.00K |
| PayablesAndAccruedExpenses | 2.97M | 2.69M | 2.08M | 2.85M |
| Payables | 2.97M | 2.69M | 2.08M | 2.85M |
| OtherPayable | 312.00K | 46.00K | ||
| AccountsPayable | 2.97M | 2.69M | 2.08M | 2.85M |
| TotalAssets | 12.48M | 12.89M | 22.02M | 40.16M |
| TotalNonCurrentAssets | 3.72M | 4.54M | 5.04M | 5.46M |
| NonCurrentPrepaidAssets | 162.00K | 167.00K | 156.00K | 191.00K |
| NonCurrentDeferredAssets | 0.00 | |||
| NonCurrentDeferredTaxesAssets | 0.00 | |||
| NonCurrentAccountsReceivable | 44.00K | 29.00K | 209.00K | |
| GoodwillAndOtherIntangibleAssets | 0.00 | 93.00K | ||
| NetPPE | 3.51M | 4.34M | 4.67M | 5.17M |
| AccumulatedDepreciation | -1.53M | -1.17M | -721.00K | -316.00K |
| GrossPPE | 5.05M | 5.51M | 5.40M | 5.49M |
| Leases | 1.16M | 1.39M | 1.44M | 1.51M |
| OtherProperties | 3.89M | 4.12M | 3.96M | 3.98M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 8.77M | 8.35M | 16.98M | 34.70M |
| CurrentDeferredAssets | 0.00 | |||
| RestrictedCash | 900.00K | 1.40M | ||
| PrepaidAssets | 955.00K | 1.69M | 2.49M | 638.00K |
| Receivables | 1.86M | 1.07M | 1.31M | 1.90M |
| OtherReceivables | 102.00K | 117.00K | 231.00K | 676.00K |
| TaxesReceivable | 1.76M | 958.00K | 1.08M | 1.23M |
| CashCashEquivalentsAndShortTermInvestments | 5.05M | 4.18M | 13.18M | 32.17M |
| CashAndCashEquivalents | 5.05M | 4.18M | 13.18M | 32.17M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -12.94M | -17.78M | -26.07M | -23.29M |
| RepaymentOfDebt | -1.14M | -697.00K | -424.00K | -289.00K |
| IssuanceOfDebt | 0.00 | 65.00K | 7.85M | 0.00 |
| IssuanceOfCapitalStock | 16.55M | 9.17M | 428.00K | 53.85M |
| CapitalExpenditure | -87.00K | -292.00K | -1.36M | |
| EndCashPosition | 5.95M | 5.58M | 13.18M | 32.17M |
| BeginningCashPosition | 5.58M | 13.18M | 32.17M | 5.83M |
| EffectOfExchangeRateChanges | 183.00K | -508.00K | -793.00K | -210.00K |
| ChangesInCash | 186.00K | -7.09M | -18.19M | 26.54M |
| FinancingCashFlow | 13.13M | 10.69M | 7.85M | 49.80M |
| CashFlowFromContinuingFinancingActivities | 13.13M | 10.69M | 7.85M | 49.80M |
| NetOtherFinancingCharges | -2.29M | -432.00K | -3.76M | |
| ProceedsFromStockOptionExercised | 0.00 | 2.59M | 0.00 | 0.00 |
| NetCommonStockIssuance | 16.55M | 9.17M | 428.00K | 53.85M |
| CommonStockIssuance | 16.55M | 9.17M | 428.00K | 53.85M |
| NetIssuancePaymentsOfDebt | -1.14M | -632.00K | 7.42M | -289.00K |
| NetLongTermDebtIssuance | -1.14M | -632.00K | 7.42M | -289.00K |
| LongTermDebtPayments | -1.14M | -697.00K | -424.00K | -289.00K |
| LongTermDebtIssuance | 0.00 | 65.00K | 7.85M | 0.00 |
| InvestingCashFlow | -3.00K | -93.00K | -268.00K | -1.33M |
| CashFlowFromContinuingInvestingActivities | -3.00K | -93.00K | -268.00K | -1.33M |
| NetInvestmentPurchaseAndSale | -3.00K | -6.00K | 24.00K | 30.00K |
| SaleOfInvestment | 24.00K | 30.00K | ||
| PurchaseOfInvestment | -3.00K | -6.00K | ||
| NetIntangiblesPurchaseAndSale | 0.00 | 0.00 | 0.00 | -60.00K |
| PurchaseOfIntangibles | 0.00 | 0.00 | 0.00 | -60.00K |
| NetPPEPurchaseAndSale | 0.00 | -87.00K | -292.00K | -1.30M |
| SaleOfPPE | 24.00K | 30.00K | ||
| PurchaseOfPPE | 0.00 | -87.00K | -292.00K | -1.30M |
| OperatingCashFlow | -12.94M | -17.69M | -25.77M | -21.93M |
| CashFlowFromContinuingOperatingActivities | -12.94M | -17.69M | -25.77M | -21.93M |
| TaxesRefundPaid | 0.00 | 1.60M | 754.00K | 846.00K |
| InterestReceivedCFO | 254.00K | 154.00K | 13.00K | 0.00 |
| InterestPaidCFO | -56.00K | -65.00K | -172.00K | -25.00K |
| ChangeInWorkingCapital | 520.00K | 1.56M | -2.88M | 1.24M |
| ChangeInPayablesAndAccruedExpense | 146.00K | 455.00K | -1.39M | -626.00K |
| ChangeInPayable | 146.00K | 455.00K | -1.39M | -626.00K |
| ChangeInAccountPayable | 449.00K | 502.00K | -599.00K | -647.00K |
| ChangeInReceivables | 374.00K | 1.11M | -1.49M | 1.86M |
| OtherNonCashItems | 641.00K | 1.36M | -530.00K | -992.00K |
| StockBasedCompensation | 357.00K | 479.00K | 942.00K | 1.38M |
| AssetImpairmentCharge | 0.00 | 0.00 | 87.00K | 0.00 |
| DeferredTax | -813.00K | -984.00K | -998.00K | -190.00K |
| DeferredIncomeTax | -813.00K | -984.00K | -998.00K | -190.00K |
| DepreciationAmortizationDepletion | 607.00K | 615.00K | 571.00K | 344.00K |
| DepreciationAndAmortization | 607.00K | 615.00K | 571.00K | 344.00K |
| Depreciation | 607.00K | 615.00K | 571.00K | 344.00K |
| OperatingGainsLosses | -3.88M | -282.00K | -395.00K | |
| GainLossOnInvestmentSecurities | -3.88M | -282.00K | -395.00K | |
| NetIncomeFromContinuingOperations | -10.57M | -22.12M | -23.17M | -24.53M |
SEC Filings
No SEC filings found for this symbol (may be non-US or ticker not in SEC index).
Public Trades for EVAX
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|